Xtant Medical (XTNT)
(Delayed Data from AMEX)
$0.95 USD
+0.05 (5.38%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $0.92 -0.03 (-3.16%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Xtant Medical Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 91 | 58 | 55 | 53 | 65 |
Cost Of Goods | 36 | 26 | 23 | 19 | 22 |
Gross Profit | 55 | 32 | 32 | 34 | 43 |
Selling & Adminstrative & Depr. & Amort Expenses | 66 | 39 | 36 | 35 | 45 |
Income After Depreciation & Amortization | -10 | -7 | -4 | -1 | -2 |
Non-Operating Income | 12 | 0 | 0 | 0 | 0 |
Interest Expense | 3 | 2 | 1 | 6 | 6 |
Pretax Income | -1 | -8 | -5 | -7 | -8 |
Income Taxes | -2 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1 | -8 | -5 | -7 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 1 | -8 | -5 | -7 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -7 | -5 | -3 | 1 | 1 |
Depreciation & Amortization (Cash Flow) | 3 | 1 | 1 | 2 | 3 |
Income After Depreciation & Amortization | -10 | -7 | -4 | -1 | -2 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 126.79 | 94.09 | 85.46 | 28.50 | 13.16 |
Diluted EPS Before Non-Recurring Items | 0.01 | -0.09 | -0.06 | -0.25 | -0.59 |
Diluted Net EPS (GAAP) | 0.01 | -0.09 | -0.06 | -0.25 | -0.63 |
Fiscal Year end for Xtant Medical Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 28.11 | 25.02 | 20.23 | 17.94 |
Cost Of Goods | NA | 10.97 | 9.69 | 7.77 | 7.41 |
Gross Profit | NA | 17.14 | 15.33 | 12.46 | 10.54 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 20.94 | 18.72 | 13.85 | 12.11 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.80 | -3.39 | -1.39 | -1.57 |
Non-Operating Income | NA | 0.90 | 11.08 | 0.00 | 0.09 |
Interest Expense | NA | 0.82 | 0.76 | 0.79 | 0.58 |
Pretax Income | NA | -3.73 | 6.93 | -2.18 | -2.07 |
Income Taxes | NA | 0.58 | -2.30 | 0.01 | 0.01 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.30 | 9.23 | -2.19 | -2.08 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.30 | 9.23 | -2.19 | -2.08 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 136.96 | 138.66 | 108.90 | 108.89 |
Diluted EPS Before Non-Recurring Items | NA | -0.03 | 0.07 | -0.02 | -0.02 |
Diluted Net EPS (GAAP) | NA | -0.02 | 0.07 | -0.02 | -0.02 |